Longitudinal undetectable molecular residual disease defines potentially cured population in localized non–small cell lung cancer
JT Zhang, SY Liu, W Gao, SYM Liu, HH Yan, L Ji… - Cancer Discovery, 2022 - AACR
The efficacy and potential limitations of molecular residual disease (MRD) detection urgently
need to be fully elucidated in a larger population of non–small cell lung cancer (NSCLC) …
need to be fully elucidated in a larger population of non–small cell lung cancer (NSCLC) …
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients
Y Pan, JT Zhang, X Gao, ZY Chen, B Yan, PX Tan… - Cancer Cell, 2023 - cell.com
The value of circulating tumor DNA (ctDNA) during chemoradiotherapy (CRT) remains
unclear but is critical for detecting molecular residual disease (MRD). In this prospective …
unclear but is critical for detecting molecular residual disease (MRD). In this prospective …
D-1553 (Garsorasib), a potent and selective inhibitor of KRASG12C in patients with NSCLC: phase 1 study results
Z Li, Z Song, Y Zhao, P Wang, L Jiang, Y Gong… - Journal of Thoracic …, 2023 - Elsevier
Abstract Introduction D-1553 (garsorasib) is a potent and selective oral KRAS G12C
inhibitor. We report results from a phase I dose-escalation and dose-expansion study of D …
inhibitor. We report results from a phase I dose-escalation and dose-expansion study of D …
[HTML][HTML] Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Molecular biomarker testing is the standard of care for non–small cell lung cancer (NSCLC)
patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean …
patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean …
Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune …
Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and
squamous pathologies, harbors strong plasticity and is significantly associated with poor …
squamous pathologies, harbors strong plasticity and is significantly associated with poor …
[HTML][HTML] Targeted therapy for rare lung cancers: Status, challenges, and prospects
C Wang, X Yuan, J Xue - Molecular Therapy, 2023 - cell.com
Lung cancer causes the most cancer-related deaths worldwide. In recent years, molecular
and immunohistochemical techniques have rapidly developed, further inaugurating an era …
and immunohistochemical techniques have rapidly developed, further inaugurating an era …
[HTML][HTML] EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes
R Jin, L Peng, J Shou, J Wang, Y Jin, F Liang… - Frontiers in …, 2021 - frontiersin.org
Background The therapeutic efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) in advanced EGFR-mutant lung squamous cell carcinoma (SCC) …
inhibitors (EGFR-TKIs) in advanced EGFR-mutant lung squamous cell carcinoma (SCC) …
[HTML][HTML] Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma
R Zhao, Y Xu, Y Chen, J Zhang, F Teng, S Liao… - NPJ Precision …, 2023 - nature.com
The genomic origin and development of the biphasic lung adenosquamous carcinoma
(ASC) remain inconclusive. Here, we derived potential evolutionary trajectory of ASC …
(ASC) remain inconclusive. Here, we derived potential evolutionary trajectory of ASC …
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and
squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is …
squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is …
[HTML][HTML] Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adeno-to-squamous transdifferentiation
Lkb1 deficiency confers the Kras-mutant lung cancer with strong plasticity and the potential
for adeno-to-squamous transdifferentiation (AST). However, it remains largely unknown how …
for adeno-to-squamous transdifferentiation (AST). However, it remains largely unknown how …